Industry News (Licensing Agreement)

Merck Licenses Vical's "Naked" DNA Technology For Antiviral Vaccines

Published in TB and Outbreaks Week, November 17th, 1997

Vical Inc., San Diego, California, announced the signing of an agreement granting Merck & Co., Inc. certain rights to develop and market therapeutic vaccines against the HIV and the hepatitis B virus (HBV) using Vical's patented "naked" DNA technology.

The new agreement grants to Merck exclusive worldwide rights to use Vical's proprietary naked DNA technology for therapeutic vaccines against HIV and HBV. Merck also holds a license to use the technology for a therapeutic vaccine against the human papilloma virus (HPV). Preventive vaccines prime the body's immune system to respond to potential future infections by foreign organisms. Therapeutic vaccines trigger or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1997-11-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry